Skip to main content

Drug Interactions between fosamprenavir and lazertinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

fosamprenavir lazertinib

Applies to: fosamprenavir and lazertinib

Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of lazertinib. To examine this interaction, healthy adult participants (n=16) received lazertinib (160 mg) on day 1, then the potent CYP450 3A4 inhibitor itraconazole (200 mg) daily on days 8 to 16. On day 12, the participants received another single dose of lazertinib (160 mg). Concomitant use of itraconazole increased lazertinib's peak plasma concentration (Cmax) and systemic exposure (AUC) by 1.2- and 1.5-fold, respectively. The clinical significance of these changes is unknown.

References (3)
  1. (2024) "Product Information. Lazcluze (lazertinib)." Janssen Biotech, Inc.
  2. Janssen Research & Development, LLC (2024) A study to assess the effects of itraconazole and rifampin on lazertinib in healthy adult participants. https://clinicaltrials.gov/study/NCT04410094?tab=table
  3. Mehta J, Haddish-Berhane N, Hellemans P, et al. (2024) PI-100-The drug-drug interaction (DDI) effect of steady state itraconazole exposure on single dose pharmacokinetics (PK) of lazertinib. https://ascpt2023.eventscribe.net/fsPopup.asp?efp=T0ZZRlFOUkgxODIxOQ&PosterID=553886&rnd=0.9604228&mode=posterInfo

Drug and food interactions

Moderate

fosamprenavir food

Applies to: fosamprenavir

ADJUST DOSING INTERVAL: Food may reduce the systemic bioavailability of amprenavir from fosamprenavir oral suspension. The mechanism of interaction has not been described. According to the product labeling, administration of fosamprenavir oral suspension (1400 mg single dose) with a high-fat meal (967 kcal, 67 g fat, 33 g protein, 58 g carbohydrate) reduced amprenavir peak plasma concentration (Cmax) by 46% and systemic exposure (AUC) by 28% compared to administration in a fasted state. The time to reach peak plasma level (Tmax) was delayed by 0.72 hours. In contrast, the same high-fat meal did not affect the pharmacokinetics of amprenavir from fosamprenavir tablets.

MANAGEMENT: Fosamprenavir suspension should be administered on an empty stomach in adults, but with food in pediatric patients to aid palatability and compliance. If emesis occurs within 30 minutes after dosing the suspension, the dose should be repeated. Fosamprenavir tablets may be taken with or without food.

References (1)
  1. (2003) "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer